Cellebrite DI Ltd. $CLBT Stock Sold by USS Investment Management Ltd

USS Investment Management Ltd trimmed its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 80.0% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 136,983 shares of the company’s stock after selling 546,998 shares during the period. USS Investment Management Ltd’s holdings in Cellebrite DI were worth $1,541,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Nine Ten Capital Management LLC raised its holdings in Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after purchasing an additional 682,933 shares in the last quarter. Wellington Management Group LLP lifted its position in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after purchasing an additional 1,475,579 shares during the period. Renaissance Technologies LLC grew its stake in shares of Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after purchasing an additional 365,700 shares during the period. Weiss Asset Management LP grew its holdings in Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the period. Finally, Ashford Capital Management Inc. raised its position in shares of Cellebrite DI by 5.5% during the 1st quarter. Ashford Capital Management Inc. now owns 1,762,937 shares of the company’s stock worth $24,293,000 after purchasing an additional 92,092 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Cellebrite DI

In other news, insider Holly B. Windham sold 3,049 shares of the stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $10.65, for a total value of $32,471.85. Following the completion of the transaction, the insider directly owned 92,279 shares in the company, valued at $982,771.35. This trade represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the completion of the transaction, the chief financial officer directly owned 322,085 shares in the company, valued at $3,610,572.85. This represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 67,822 shares of company stock worth $761,343 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

CLBT has been the topic of several recent research reports. DA Davidson restated a “buy” rating and set a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. Weiss Ratings raised Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, November 13th. Lake Street Capital dropped their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, November 13th. Finally, Needham & Company LLC lifted their price target on shares of Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research report on Thursday, November 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.75.

View Our Latest Stock Report on CLBT

Cellebrite DI Trading Down 4.9%

Shares of NASDAQ CLBT opened at $10.77 on Friday. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.39. The business has a 50 day simple moving average of $11.56 and a 200-day simple moving average of $13.12. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 1.36 and a beta of 1.06.

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Recommended Stories

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.